Navigation Links
New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
Date:6/11/2009

global Phase 3 clinical trials in adults, with regulatory submissions expected in 2010.

Pneumococcal Disease

Pneumococcal disease is complex and describes a group of illnesses, all caused by the bacterium Streptococcus pneumoniae. Pneumococcal disease affects both children and adults, and includes invasive infections such as bacteremia/sepsis and meningitis, as well as pneumonia and otitis media (middle ear infection).

Most recently serotype 19A, which is included in the candidate vaccine, has been increasing in prevalence in many regions of the world and is frequently resistant to antibiotics.

Indication for Prevenar

Prevenar is indicated for active immunization against disease by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (including sepsis, meningitis, pneumonia, bacteremia, and acute otitis media) in infants and children from 2 months up to 5 years of age.

Important Safety Information for Prevenar

In clinical studies (n=18,168), the most frequently reported adverse events included injection site reactions, fever (greater than or equal to 38 degrees C/100.4 degrees F), irritability, drowsiness, restless sleep, decreased appetite, vomiting, diarrhea, and rash.

Risks are associated with all vaccines, including Prevenar. Hypersensitivity to any vaccine component, including diphtheria toxoid, is a contraindication to its use. Prevenar does not provide 100% protection against vaccine serotypes or protect against non vaccine serotypes. The decision to administer Prevenar should be based on its efficacy in preventing invasive pneumococcal disease (IPD).

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervou
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SILVER SPRING, Md., July 29, 2014  United ... today announced its financial results for the ... "Our continued growth shows that our medicines ... from pulmonary arterial hypertension (PAH)," said Martine ... Executive Officer. "The commercial launch this quarter ...
(Date:7/29/2014)... 2014 Dr. Jason Wendel – recipient of ... one of the Top 10 Plastic Surgeon Specialists for Nashville, ... products. His complete line includes a Hydration Booster, Retexturing Night ... face and skin a younger, more radiant appearance while protecting ... is different, that is why at Dr. J. J. Wendel ...
(Date:7/28/2014)... 2014 Sapphire Energy, Inc. , a ... appointment of biotechnology veteran James Levine as ... Levine replaces Cynthia ,CJ, Warner, who is stepping down ... of the company,s board of directors. "The ... deliver commercial scale algae-based fuels has been tremendous, from ...
(Date:7/28/2014)... DUBLIN , July 28, 2014 ... the "Global Synthetic Biology Market 2014-2018" report ... The term synthetic biology covers the ... and organisms as well as the redesigning of natural ... is considered to be a form of extreme genetic ...
Breaking Biology Technology:United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Global Synthetic Biology Market 2014-2018 2
... (Nasdaq: SIAL ) is pleased to announce ... Chief Information Officer, effective August 16, 2010. In his ... systems function and will report to Rakesh Sachdev, Sr. ... Borg (age 50) brings over two decades ...
... Unaudited Second Quarter Results -- re> SHENYANG, China, Aug. 17 /PRNewswire-Asia-FirstCall/ -- ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Statement re ProAmatine -- PHILADELPHIA, Pennsylvania, August 17, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:Sigma-Aldrich Announces Appointment of Magnus Borg as Vice President and Chief Information Officer (CIO) 23SBio Inc. Announces Unaudited Second Quarter Results 23SBio Inc. Announces Unaudited Second Quarter Results 33SBio Inc. Announces Unaudited Second Quarter Results 43SBio Inc. Announces Unaudited Second Quarter Results 53SBio Inc. Announces Unaudited Second Quarter Results 63SBio Inc. Announces Unaudited Second Quarter Results 73SBio Inc. Announces Unaudited Second Quarter Results 83SBio Inc. Announces Unaudited Second Quarter Results 93SBio Inc. Announces Unaudited Second Quarter Results 103SBio Inc. Announces Unaudited Second Quarter Results 113SBio Inc. Announces Unaudited Second Quarter Results 123SBio Inc. Announces Unaudited Second Quarter Results 133SBio Inc. Announces Unaudited Second Quarter Results 143SBio Inc. Announces Unaudited Second Quarter Results 153SBio Inc. Announces Unaudited Second Quarter Results 163SBio Inc. Announces Unaudited Second Quarter Results 173SBio Inc. Announces Unaudited Second Quarter Results 183SBio Inc. Announces Unaudited Second Quarter Results 19Shire plc - Statement re ProAmatine 2Shire plc - Statement re ProAmatine 3Shire plc - Statement re ProAmatine 4Shire plc - Statement re ProAmatine 5Shire plc - Statement re ProAmatine 6
(Date:7/29/2014)... July 29, 2014  When it comes to technology, healthcare is ... not the last. However, when it comes to wearables, healthcare is ... market for the Internet of Things and its wearable cousins is ... in the healthcare industry, whether it,s in the hospital for a ... fit. With that in mind, InformationWeek editor Rodney ...
(Date:7/29/2014)... Aarhus University researchers have developed an easier method ... strengthen the work involved in diagnosing diseases. , ... provides a strong partnership that can be used ... conjugates which tag proteins with DNA ... sensitive detection and visualisation of biological material. The ...
(Date:7/29/2014)... University of Maryland Schools of Dentistry (UM SOD) ... they have received a five-year $10.7 million grant ... Infectious Diseases (NIAID) of the National Institutes of ... of sexually-transmitted diseases (STDs). The grant, which renews ... represents a new direction for the research by ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4
... was launched today by the Chinese National Space Administration ... Centre, Sichuan, atop a Long March 3A rocket. ... to land robotic explorers on the Moon before 2020. ... first is to make three-dimensional images of many lunar ...
... and Ludwigshafen, Germany-October 24, 2007-Harvard University,s Office of ... agreement to jointly establish the BASF Advanced Research ... of Engineering and Applied Sciences (SEAS) the initiative ... and schools throughout the University. Set up ...
... Researchers at the University of Minnesotas Stem Cell Institute ... used to study how human embryonic stem cells differentiate. ... Experimental Biology and Medicine. Researchers know very little ... fully understand these cells self renewal capacity and pluripotency, ...
Cached Biology News:Chang'e-1 -- new mission to Moon lifts off 2BASF and Harvard University announce extensive research collaboration 2